IN THE CLAIMS:

32. (Currently amended) A method for treatment of a disease affectable by Factor VIIa (FVIIa), said method comprising administering subcutaneously to a mammal in need thereof an effective amount for treating said disease of a composition comprising modified FVIIa~~, wherein said modified FVIIa has substantially the same biological activity for blood coagulation as authentic FVIIa~~.

33. (Currently amended) A method for prolonging the biological half-life of Factor VIIa (FVIIa) being administered to a mammal, said method comprising administering to a mammal in need thereof by subcutaneous injection a composition comprising modified FVIIa~~, wherein said modified FVIIa has substantially the same biological activity for blood coagulation as authentic FVIIa~~.--

34. (Previously presented) The method of claim 32 wherein the disease is haemophilia A or B.

35. (Currently amended) The method of claim 32 wherein the modified Factor VIIa is ~~recombinant~~ modified human Factor VIIa that has been produced recombinantly.--

36. (Previously presented) The method of claim 32 wherein the composition is a stable aqueous solution ready for administration.

37. (Previously presented) The method of claim 32 wherein the composition is dried and reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.

38. (Previously presented) The method of claim 33 wherein said mammal suffers from haemophilia A or B.

39. (Currently amended) The method of claims 33 wherein the Factor VIIa is ~~recombinant~~ modified human Factor VIIa that has been produced recombinantly.--

40. (Previously presented) The method of claim 33 wherein the composition is a stable aqueous solution ready for administration.

41. (Previously presented) The method of claim 33 wherein the composition is dried and reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.